A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): Responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67

Bojana Jovanovic, Ingrid A. Mayer, Erica L. Mayer, Vandana G. Abramson, Aditya Bardia, Melinda E. Sanders, M. Gabriela Kuba, Monica V. Estrada, J. Scott Beeler, Timothy M. Shaver, Kimberly C. Johnson, Violeta Sanchez, Jennifer M. Rosenbluth, Patrick M. Dillon, Andres Forero-Torres, Jenny C. Chang, Ingrid M. Meszoely, Ana M. Grau, Brian D. Lehmann, Yu ShyrQuanhu Sheng, Sheau Chiann Chen, Carlos L. Arteaga, Jennifer A. Pietenpol

Research output: Contribution to journalArticlepeer-review

83 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): Responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67'. Together they form a unique fingerprint.

Medicine & Life Sciences